Early Access — free while we kick the tires
EdgarHawk

Winer Gary M

Director

Director
7 filings analyzed · 2 companies · Latest 2025-05-20

Companies

Company Buys Sells Direction
HCW Biologics Inc. HCWB 2 0 Net buying
LENSAR, Inc. LNSR 10 0 Net buying

Activity

May 2025
2025-05-20 HCW Biologics Inc. HCWB
high
Buy
1,342 shares
$9,998
Significance 6/10

Director Winer buys 1,342 shares of HCWB at $7.45; stock down 81.5% from 52-week high; cluster of 5 other insiders also bought in past 14 days.

Director Gary M Winer purchased 1,342 shares at $7.45 on 2025-05-16, increasing his holdings by 49.1% from 2,733 to 4,075 shares. The transaction occurs at a steep discount to the 52-week high of $49.60 (stock now at $9.18, down 81.5%), yet the company is unprofitable with a net income of $-2,196,875.00 and declining annual revenue growth of -9.7%. Notably, this purchase is part of a cluster pattern: 5 other insiders also bought within the past 14 days, and Winer himself made another buy 8 days prior on 2025-05-08. While Winer's cross-ticker track record shows a 90d win rate of 92.86% with average 90d returns of +38.6%, his prior HCWB trades have no measurable 90-day outcomes yet, making it difficult to assess whether this accumulated buying reflects conviction in a recovery or represents accumulation at depressed levels amid deteriorating fundamentals.

2025-05-09 HCW Biologics Inc. HCWB
high
Buy
2,308 shares
$60,008
Significance 8/10

Director Winer buys 2,308 shares at $26.00 after 5 prior well-timed HCWB buys showed +2100–2319.5% 90d returns; stock down 87.5% from $49.60 high.

Winer Gary M increased his HCWB stake by 543.1% to 2,733 shares with a $60,008.00 purchase at $26.00, at a moment when the stock has fallen to $6.18—87.5% below its 52-week high and down 35.4% in 30 days. His 5 prior HCWB purchases (September 2023) each demonstrated exceptional 90-day timing, with returns ranging from 2046.3% to 2319.5%, suggesting a pattern of precision in entry points at this ticker. However, the company remains unprofitable with $-3.9M net income in its most recent fiscal year and annual revenue decline of -9.7%, creating a fundamental disconnect between prior timing success and current valuation. A cluster pattern is present: 5 other insiders also bought within the past 14 days. The magnitude of price deterioration since his last trades and the unprofitable state of the business warrant scrutiny of whether historical patterns hold in a materially changed market and operating environment.

September 2024
2024-09-06 LENSAR, Inc. LNSR
medium
Buy
685 shares
$3,082
Significance 5/10

Director Winer buys 685 LNSR shares at $4.50 on 2024-09-03; 5 consecutive buys in 8 days despite -16.7% from 52-week high and -$9.0M net loss.

Director Gary M Winer purchased 685 shares at $4.50 on 2024-09-03, bringing holdings to 80,840 shares and marking the fifth consecutive buy across August 21–September 3, 2024. This concentrated buying activity occurred while the stock trades -16.7% from its 52-week high and the company posted a net loss of $9.0M against quarterly revenue of $12.6M, indicating ongoing unprofitability. Winer's cross-ticker track record shows a 100.00% 90-day win rate across 20 prior buys with +1417.0% average 90-day return, but none of his five prior LNSR trades have yet reached measurable 90-day outcomes. The rapid succession of purchases in a single week, combined with fundamental headwinds and the company's negative earnings, presents a pattern worth tracking as results emerge.

August 2024
2024-08-29 LENSAR, Inc. LNSR
high
Buy
2,302 shares
$10,373
Significance 6/10

Director Winer purchases 2,302 shares across 3 transactions at $4.51 avg (Aug 26–28); stock down 8.8% in 30 days.

Gary M Winer, a director at LENSAR, Inc., completed 3 separate purchases totaling 2,302 shares for $10,373.16 between August 26 and August 28, 2024, at a blended average price of $4.51, raising his holdings from 77,853 to 80,155 shares (+3.0%). The purchases occur during a period of material downward pressure: the stock is down 8.8% over the last 30 days and trades at $4.65, a 14.5% discount to its 52-week high of $5.44. The company is currently unprofitable (net income of $-9.0M in the latest quarter) despite 19.2% annual revenue growth. Notably, this director has engaged in 4 prior purchases at LNSR within the preceding 6 trading days (August 14, 16, 20, 21, and 22), establishing a pattern of repeated accumulation. While his cross-ticker track record shows strong outcomes (92.86% 90-day win rate on 20 prior buys with average +1438.8% return), his same-ticker outcomes at LNSR remain unmeasurable due to recent timing. The rapid-fire buying pattern in a declining stock amid operational losses merits tracking, particularly whether this accumulation reflects a conviction opportunity or represents a commitment independent of near-term price momentum.

2024-08-23 LENSAR, Inc. LNSR
high
Buy
502 shares
$2,185
Significance 6/10

Director Winer buys 502 LNSR shares for $2,184.60; 5 consecutive buys in 9 days amid unprofitable operations.

Winer Gary M, a director at LENSAR Inc., executed two purchases totaling 502 shares for $2,184.60 (blended average $4.35) on 2024-08-21 and 2024-08-22. This represents his fifth consecutive open-market buy over a nine-day span (2024-08-12 through 2024-08-22), bringing his holdings to 77,853 shares. The company is unprofitable with $-9.0M net income in its most recent full fiscal year, though it posted +19.2% annual revenue growth and currently trades at a $54.8M market cap. The sustained pace of small incremental purchases at prices ranging $4.30–$4.35 during a period when the stock has declined 9.1% over the past 30 days contrasts with the director's cross-ticker track record of strong timing (90-day win rate 86.67%, avg 90d return +1339.8%), though measurable outcomes on his same-ticker LNSR trades remain undetermined. The clustering of discretionary open-market buys warrants examination of the underlying business dynamics and whether the director perceives value below current market levels.

2024-08-20 LENSAR, Inc. LNSR
high
Buy
506 shares
$2,124
Significance 6/10

Director Winer purchases 506 shares at $4.20 blended average; stock down 17.5% in 30 days amid -$9.0M net loss.

Winer Gary M (Director) executed 2 purchases totaling 506 shares for $2,124.18, raising his holdings to 77,351 shares, in a company with $12.6M quarterly revenue but a -$9.0M net loss in its most recent full fiscal year. The purchases occurred at $4.03 and $4.20 against a current price of $4.06, following sharp recent deterioration: the stock is down 17.5% over 30 days and trades 25.4% below its 52-week high of $5.44. His same-ticker transaction history shows 3 measurable prior buys at LNSR, all of which generated positive 90-day returns (50.5%, 9.6%, and 8.4%), establishing a strong timing pattern at this specific ticker. The concentrated nature of this purchase—two buys within six calendar days in mid-August—alongside his demonstrated ability to enter at inflection points at LNSR (based on 90-day historical win rate of 3 of 3) contrasts sharply with the company's current unprofitable state and the broader downward momentum in the equity.

2024-08-14 LENSAR, Inc. LNSR
medium
Buy
1,500 shares
$6,215
Significance 6/10

Director Winer buys 1,500 LNSR shares in 2 tranches for $6,215.00; 4 of 5 prior buys at ticker well-timed at 90d, but stock down 22.1% in 30d and -26.3% from high.

Winer Gary M, a director, purchased 1,500 shares across two open-market transactions on 2024-08-12 and 2024-08-14 at an average price of $4.14, increasing his holdings from 75,345 to 76,845 shares (+2.0%). His same-ticker history at LNSR shows 4 of 5 prior buys were well-timed at the 90-day mark, with recent purchases in November 2023 generating 90-day returns of +50.5%, +9.6%, +8.4%, and +5.8% respectively. However, this purchase occurs as the stock has fallen 22.1% over the past 30 days and trades 26.3% below its 52-week high of $5.44, currently at $4.01 — below the transaction prices. The company posted net income of $-9.0M against quarterly revenue of $12.6M and remains unprofitable on a full-year basis, though it showed annual revenue growth of +19.2%. The timing of this accumulation against recent weakness and ongoing losses requires assessment of whether it reflects conviction in a depressed-valuation entry or simply routine portfolio activity by a board member.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access